HbA1c News and Research

RSS

Semaglutide approval drove a surge in GLP-1 poison center exposures

Following semaglutide's approval, poison center reports of GLP-1 RA exposures doubled, revealing critical trends in patient safety and healthcare utilization.

26 Jun 2026

Early diabetes drug treatment links to better survival after diagnosis thresholds

A Korean target trial emulation found that starting antidiabetic medication within 12 months of newly crossing type 2 diabetes diagnostic thresholds was associated with lower five-year all-cause mortality. MACE risk was numerically lower with earlier treatment, but the reductions in cardiovascular events were not statistically significant, underscoring the need for larger studies.

24 Jun 2026

The importance of ketones from a clinical and medical perspective

In this interview, News-Medical talks to Marcin Pacek, senior director of medical and scientific affairs in Europe for Nova Biomedical, about the importance of ketones in a medical and clinical setting.

From Nova Biomedical 15 Jun 2026

Oral semaglutide improves blood sugar, weight, and liver markers in real-world diabetes care

A nationwide Finnish registry study of 7,249 GLP-1RA-naïve adults with type 2 diabetes found that once-daily oral semaglutide was associated with 12-month improvements in HbA1c, body weight, lipid markers, and ALT.

11 Jun 2026

The best meal timing for blood sugar may be earlier dinners

...

9 Jun 2026

Oral GLP-1 RA reduces blood glucose and bodyweight among people with type 2 diabetes

Oral GLP-1 medications have the potential to increase access to therapies that can help lower blood sugar and reduce bodyweight.

8 Jun 2026

NHS online diabetes program improves blood sugar and pressure

NHS England's Healthy Living program offers modest diabetes improvements; addressing engagement and access could enhance its public health effectiveness.

8 Jun 2026

Brain tumor removal may improve blood sugar in diabetes patients

A new study published today in JAMA Network Open found that removing olfactory groove meningioma - a type of brain tumor located near the base of the brain - may improve blood sugar control in patients with diabetes.

3 Jun 2026

Retatrutide reshapes metabolism in obesity and type 2 diabetes, study finds

Retatrutide altered circulating metabolites and lipids linked to fatty acid oxidation and insulin resistance in people with obesity, with or without type 2 diabetes. These biomarker changes suggest improved metabolic health, but the post-hoc analysis remains hypothesis-generating and does not prove direct clinical benefit.

26 May 2026

HonorHealth Research Institute tests steam therapy for diabetes treatment

HonorHealth Research Institute is looking to become the first research facility in the nation to begin a new clinical trial that aims to modify the lining of the digestive tract with the use of steam energy to control type II diabetes without the use of drugs.

21 May 2026

Pregnancy-related disorders may shape offspring heart health into adulthood

Hypertensive disorders in pregnancy may lead to lasting cardiovascular issues in offspring, highlighting the need for improved maternal health strategies.

19 May 2026

New therapies could help type 1 diabetes care move beyond insulin alone

Disease-modifying therapies for type 1 diabetes are beginning to move care beyond insulin replacement by targeting immune dysregulation, beta-cell stress, and preservation of endogenous beta-cell function. Teplizumab marks a major clinical milestone, but the review emphasizes that durable metabolic remission will likely require earlier screening, better patient selection, and sequential or combination therapies.

18 May 2026

Study traces adult heart disease risk back to the womb

A child's future heart health may be partially shaped before they are born, reports a new Northwestern Medicine study that found pregnancy complications are linked to poorer cardiovascular health in offspring more than 20 years later.

14 May 2026

Could GLP-1 drugs help breast cancer patients live longer?

A large retrospective cohort study of adult female breast cancer patients found that GLP-1 receptor agonist use was associated with better all-cause survival and recurrence-free survival in patients with obesity or type 2 diabetes. The strongest associations were seen versus non-use in obesity and versus insulin or metformin in type 2 diabetes, while comparisons with SGLT2 inhibitors were less consistent and require further study.

12 May 2026

Maternal insulin resistance linked to higher abdominal fat in girls

Girls born to mothers with higher insulin resistance during the third trimester are more likely to have more abdominal fat at age 7, according to research presented at the 28th European Congress of Endocrinology in Prague.

12 May 2026

Why are so many mothers missing diabetes follow-up after childbirth?

A New York City cohort study found that few women with postpartum-onset diabetes received guideline-recommended A1C monitoring over three years. Non-Hispanic Black women and mothers with more children faced lower monitoring rates, while Medicaid coverage was linked to better follow-up.

11 May 2026

Two leading heart risk tools pass a major global test

A multinational Nature Medicine validation study found that PREVENT and SCORE2 cardiovascular risk equations performed generally well across 6.4 million people from observational cohorts and randomized trials. The findings support broader use of these tools for CVD risk stratification, while highlighting the need for local calibration and more validation in underrepresented regions.

11 May 2026

Semaglutide shows sustained weight loss benefits in older adults

A new analysis of the STEP trails carried out by semaglutide manufacturer Novo Nordisk has analysed various trials to show the safety and efficacy of the obesity drug semaglutide in older adults (over 65 years), and found similar efficacy and safety as in the general trial populations .

11 May 2026

Daily orforglipron treatment reduces weight and blood sugar in seniors

A new analysis to be presented at this year's European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12-15 May) examined daily oral orforglipron treatment for the treatment of obesity, with or without diabetes, in users aged 65 years and over, with results and a safety profile similar to that seen in the ATTAIN clinical trial programme population.

11 May 2026

Bariatric surgery offers greater long-term health protection for seniors than GLP-1 drugs

Metabolic and bariatric surgery offers significantly greater long-term protection against heart attack, stroke and death than widely-used GLP-1 drugs in older adults with obesity and diabetes, according to new real-world analysis study presented today at the annual meeting of the American Society for Metabolic and Bariatric Surgery.

6 May 2026